Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
about
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's diseaseCholinesterase inhibitors for Parkinson's disease dementiaPresentation and management of psychosis in Parkinson's disease and dementia with Lewy bodiesParkinson Disease and Dementia.Treatment of psychosis and dementia in Parkinson's disease.Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.Treatment of advanced Parkinson's diseaseHeterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.Donepezil: a clinical review of current and emerging indications.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's diseaseLewy body and parkinsonian dementia: common, but often misdiagnosed conditions.Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.A recommended scale for cognitive screening in clinical trials of Parkinson's disease.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Parkinson's psychosis.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.An update expert opinion on management and research strategies in Parkinson's disease psychosisBehavioral disturbances in Parkinson's diseaseDonepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.Pharmacotherapy of dementia with Lewy bodies.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.Psychosis in Parkinson's disease.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.Treatment of behavioural symptoms and dementia in Parkinson's disease.Pharmacologic treatment of adolescent and child schizophrenia.A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.Donepezil: a review.Emerging drugs for Parkinson's disease.Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.Recognition and management of neuropsychiatric complications in Parkinson's disease.Outcome measures for Parkinson's disease dementia: a systematic review.Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
P2860
Q24201307-9A7B3C0D-4BE7-4525-9FD1-746B36210463Q24244668-DDFD6893-E5A7-44D4-B5F4-232979BCB049Q24680260-75519E83-F6D3-44A6-B40C-62C55BDCEAC5Q30248574-C1EBF554-9692-41AF-842D-5475D907F05BQ30358337-C470DDBA-42F3-42E9-9577-3CBA1F4D5709Q30436664-5CCF4285-7717-4401-A90E-0E19BCDB2FC4Q30476968-89387268-BC58-4B93-89C6-BF98DD5CF242Q30982993-AA5AE2E8-7634-41EA-A6FC-C2B12FEE8E84Q33150809-AF31DDB0-ED3C-46C6-A775-4018E27B09E0Q33260251-F0959A1D-F113-4D42-A4C8-9FBB9B2625C0Q33607256-6D6679C2-8B38-4B12-9082-B28BC30D3F8FQ33724257-41C8FD46-A67C-4776-8D9C-3E43636BAE00Q34032505-3DD316C9-3001-48D4-B0D4-DBA4D311BE86Q34300160-F0B7CAF0-F7FF-401F-937F-78C369B9E59BQ34388686-71D9A650-5118-4765-B610-7457C5FAC3DFQ34610593-7429BB6B-B6CC-4ED7-9111-22B8FB0BB68AQ34610608-E7400BE9-2D39-46A7-AEAF-F4FC4B72B559Q34610632-37E3E15E-B44A-447F-B6F6-9E20D2311DFEQ35057288-199DC711-3F85-4F72-8823-7ACD45AB9741Q35154278-CDD5E657-5756-4385-B56D-4C75346FE7DBQ35236819-0D638943-C6D3-469C-8A84-DB38016CFD08Q35488511-DB84D8E1-1175-40E2-A335-3A1878B55563Q35574995-59030D34-0B0C-42A0-B264-A8427766D5C0Q35614156-61C8A960-811C-4158-9FC9-FE64D3323086Q35687749-8147F4AE-43FC-43BF-9F53-E73547CFEBB6Q35863404-7FD76DDE-E9CE-47B1-829B-221D5257F23AQ35863422-2EF4E01B-4560-441D-ABA9-2769AC3779F9Q35873720-1DBFCE8F-A5E1-411B-917A-F54C07002E70Q36089350-FD07C65F-ED98-48E4-8F88-F2B711340E19Q36107249-4E524E9A-83F9-4708-9667-D2CEEA001081Q36118555-7452091E-E0F6-48CC-B4CE-DC4D3297FA89Q36351543-F34E4D4F-1F3B-4AF3-A608-11189DC6E1F6Q36486037-0D0D2B53-9A40-4A09-BC57-B72460245290Q36544994-0B5D0097-24A7-422D-8AFC-D8F00CCE6876Q36580572-FD434E84-F685-44B4-B5F2-11367D1EA2F6Q36632771-24972A79-8684-411E-915A-BB3A8B114055Q36673715-ADEA1A33-B211-42D8-AD1C-148E36B2667DQ36688859-C2A3847E-30AC-48C6-A671-12DDC4916A73Q36772321-A17E3D9E-6253-49DD-ACF6-9A7E89D30B23Q36846711-8BE154B2-1CD8-492C-B272-97269853B96C
P2860
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@ast
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@en
type
label
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@ast
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@en
prefLabel
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@ast
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@en
P2860
P356
P1476
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
@en
P2093
P2860
P304
P356
10.1136/JNNP.72.6.708
P407
P577
2002-06-01T00:00:00Z